Treatment of mastocytosis with masitinib
US10045978B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2015 |
| Grant date | Aug 14, 2018 |
| Priority date | — |
| Expiry date | Dec 2, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/095
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.